URAT1 inhibitor and use thereof

What is claimed is: 
     
       1. A compound or pharmaceutically acceptable salt thereoffor treating and preventing a metabolic disease in uric acid excretion, wherein the compound is selected from the group consisting of:
 (3,5-dibromo-4-hydroxyphenyl)(2-ethylimidazo[1,2-a]pyrimidine-3-yl)methanone; 
 (3,5-dibromo-4-hydroxyphenyl)(2-ethylimidazo[2,1-b]thiozole-5-yl)methanone; 
 (3,5-dibromo-4-hydroxyphenyl)(2-ethylimidazo[1,2-a]pyrazine-3-yl)methanone; 
 3-bromo-5-[(2-ethylimidazo[1,2-a]pyridine-3-yl)hydroxymethyl]-2-hydroxybenzonitrile; 
 5-[(2-ethylimidazo[1,2-a]pyridine-3-yl)hydroxymethyl]-2-hydroxybenzonitrile; 
 2,6-dibromo-4-[(6-ethylimidazo[2,1-b]thiozole-5-yl)hydroxymethyl]phenol; 
 2,6-dibromo-4-[(2-ethylimidazo[1,2-a]pyrazine-3-yl)hydroxymethyl]phenol; 
 2-bromo-4-[(2-ethyl-6-fluoroimidazo[1,2-a]pyridine-3-yl)hydroxymethyl]-6-fluorophenol; 
 2,6-dibromo-4-[(2-ethylpyrazolo[1,5-a]pyridine-3-yl)hydroxymethyl]phenol; 
 2,6-dibromo-4-[(6-bromo-2-ethylimidazo[1,2-a]pyridine-3-yl)hydroxymethyl]phenol; 
 2,6-dibromo-4-{[(2-ethyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-yl)]hydroxymethyl}phenol; 
 2,6-dibromo-4-[(2-ethylimidazo[1,2-a]pyridine-3-yl)methyl]phenol; 
 (3,5-dibromo-4-hydroxyphenyl)(6-ethylimidazo[2,1-b] [1,3,4]thiodiazole-5-yl)methanone; 
 2-bromo-4-(2-ethylimidazo[1,2-a]pyridine-3-yl)hydroxymethyl-6-methylphenol; 
 2,6-dibromo-4-{(2-ethyl-7-methoxyimidazo[1,2-a]pyridine-3-yl)hydroxymethyl}phenol; 
 (3,5-dibromo-4-hydroxyphenyl)(2-propylfuro[2,3-b]pyridine-3-yl)methanone. 
 
     
     
       2. A pharmaceutical acceptable composition comprising the compound of  claim 1  or its pharmaceutically acceptable salt as active ingredient, and a pharmaceutically acceptable carrier. 
     
     
       3. A method for treating and preventing a metabolic disease in uric acid excretion comprising a step of administrating to a subject in need a therapeutically effective amount of the compound of  claim 1  or its pharmaceutically acceptable salt; wherein the metabolic disease in uric acid excretion is hyperuricemia or gout. 
     
     
       4. A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 the 
 
       
         
           
           
               
               
           
         
         Y is carbonyl, sulfur, sulfone, sulfoxide, optionally substituted methylene, or imino, provided that when D is N such that the ring A forms a pyridine ring, Y is not a carbonyl group; 
         each R 1  is independently selected from the group consisting of hydrogen, deuterium, hydroxy, halogen, nitro, amino, cyano, C 1-3  alkyl, substituted C 1-3  alkyl, substituted C 1-3  amino, C 1-3  alkoxy, and substituted C 1-3  alkoxy; 
         R 2  is selected from the group consisting of hydroxy, halogen, nitro, amino, cyano, C 1-3  alkyl, substituted C 1-3  alkyl, and substituted C 1-3  amino; 
         R 3  is selected from the group consisting of C 1-4  alkyl, substituted C 1-4  alkyl, and halogen; 
         m is an integer from 0 to 3; 
         n is an integer from 1 to 3; and 
         the substituent in the group R 1 , R 2  or R 3  is each independently selected from the group consisting of hydroxyl, halogen, nitro, amino, and cyano. 
       
     
     
       5. The compound of  claim 4 , wherein Y is carbonyl. 
     
     
       6. The compound of  claim 4 , wherein each R 1  is independently selected from the group consisting of hydrogen, halogen, and C 1-3  alkyl substituted with halogen. 
     
     
       7. The compound of  claim 4 , wherein R 2  is selected from the group consisting of halogen, cyano, and C 1-3  alkyl substituted with halogen. 
     
     
       8. The compound of  claim 4 , wherein R 3  is ethyl or propyl. 
     
     
       9. The compound of  claim 4 , wherein m is 1. 
     
     
       10. The compound of  claim 4 , wherein R 1  is —H. 
     
     
       11. The compound of  claim 4 , having Formula II-A: 
       
         
           
           
               
               
           
         
       
       wherein the 
       
         
           
           
               
               
           
         
        
       
     
     
       12. A compound having the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
       13. The compound of  claim 4 , having the Formula II-B: 
       
         
           
           
               
               
           
         
       
       wherein the 
       
         
           
           
               
               
           
         
        
       
     
     
       14. A compound having the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
       15. The compound of  claim 4 , having the Formula II-C: 
       
         
           
           
               
               
           
         
       
       wherein the 
       
         
           
           
               
               
           
         
        
       
     
     
       16. The compound of  claim 4 , having the Formula V-B: 
       
         
           
           
               
               
           
         
       
       wherein the 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
        
       
     
     
       17. The compound of  claim 16 , having the following structure: 
       
         
           
           
               
               
           
         
        
       
     
     
       18. A composition, comprising the compound of  claim 4 , a pharmaceutically acceptable salt thereof, or a hydrolyzable prodrug thereof, and a pharmaceutically acceptable excipient. 
     
     
       19. A composition, comprising the compound of  claim 4  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
       20. A method for treating or preventing hyperuricemia or gout, comprising administrating to a subject in need thereof a therapeutically effective amount of the compound of  claim 4  or a pharmaceutically acceptable salt thereof.